Sorriso Pharmaceuticals

Sorriso Pharmaceuticals is developing novel orally delivered cytokine antibodies for the treatment of inflammatory diseases. Their proprietary platform, Vorabodies, leverages single-domain antibodies designed to be stable in the harsh digestive environment and maintain activity throughout the intestinal system allowing them to target inflamed tissues. Their platform allows for oral administration of antibody therapies, offering a more convenient and potentially less invasive option for patients. Sorriso's lead program targets Crohn's disease and ulcerative colitis, two chronic conditions characterized by inflammation in the digestive tract. Sorriso's lead product candidate, SOR102, is a bispecific antibody in Phase 1b clinical trial for the treatment of moderate-to-severe ulcerative colitis. Sorriso is also exploring additional antibody candidates for other inflammatory diseases.

Jobs: